The U.S. Patent and Trademark Office has provided updated guidance on the question of patent subject matter eligibility for inventions that rely on artificial intelligence, stating that a patent claim that does little more than recite an abstract idea is not subject-matter eligible.
A team of researchers from the University of Northumbria filed for protection of a flexible transdermal patch taht uses surface acoustic wave technology they believe offers distinct advantages over traditional transdermal patches.
Gasherbrum Bio Inc. has described GLP-1 receptor agonists reported to be useful for the treatment of type 2 diabetes, dyslipidemia, hyperglycemia, hypertension, obesity, stroke, myocardial infarction and gout, among others.
Immunophage Biomedical Co. Ltd. has synthesized macrophage migration inhibitory factor (MIF) inhibitors reported to be useful for the treatment of cancer and inflammation.
Exelixis Inc. has disclosed membrane-associated tyrosine- and threonine-specific Cdc2-inhibitory kinase (PKMYT1) inhibitors reported to be useful for the treatment of cancer.
Gluetacs Therapeutics (Shanghai) Co. Ltd. has synthesized oxoisoindolinyl substituted piperidinedione derivative molecular glue degraders characterized as IKZF1, IKZF3 and GSPT1 degradation inducers. They are reported to be useful for the treatment of cancer, anemia, liver failure, diabetes, infections, sarcoidosis, autoimmune diseases and cardiovascular disorders.
An Iongen Therapeutics Co. Ltd. patent reports transient receptor potential vanilloid 3 (TRPV3) receptor antagonists that are potentially useful for the treatment of acne, diabetes, anxiety, gastrointestinal, inflammatory and respiratory disorders, neurodegeneration and obesity, among others.
Jiangsu Vcare Pharmatech Co. Ltd. has created new proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase-binding moiety covalently linked to estrogen receptor α (ER-α)-binding moiety through a linker. They are reported to be useful for the treatment of cancer and infections.
RSS
